JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v10i3.14523ArticleIn Adults with Type 1 Diabetes, is the Artificial Pancreas System More Effective than Open-loop Systems in Controlling Blood Glucose?https://artdesignp.com/journal/JCNR/10/3/10.26689/jcnr.v10i3.14523LiuBo20261032026-04-22Background: Despite advances in continuous glucose monitoring (CGM) and insulin pump therapy, many adults with type 1 diabetes (T1D) do not consistently achieve recommended glycemic targets. Automated insulin delivery (AID), often referred to as the artificial pancreas (AP), integrates CGM, an insulin pump, and a control algorithm to adjust insulin delivery in real time. Objective: To summarize contemporary evidence comparing AP/AID (closed-loop or hybrid closed-loop) with open-loop approaches (e.g., sensor-augmented pump therapy or user-directed insulin dosing) for glycemic control in adults with T1D. Methods: We synthesized evidence from recent randomized controlled trials (RCTs) and meta-analyses in adults with T1D, focusing on clinically meaningful CGM-derived metrics (time in range [TIR], time below range), HbA1c, and safety outcomes. Reporting principles align with PRISMA 2020 where applicable. Results: Across modern RCTs and meta-analyses, AP/AID consistently improves TIR and reduces hyperglycemia compared with open-loop strategies, without increasing hypoglycemia. Key trials in older adults show clinically relevant gains in TIR with closed-loop systems versus sensor-augmented pump therapy. Meta-analytic evidence supports improved TIR and modest HbA1c reductions with closed-loop compared with open-loop approaches. Conclusion: In adults with T1D, AP/AID systems are more effective than open-loop regimens in improving glycemic control, offering better TIR and comparable or improved hypoglycemia safety profiles.

Gregory G, Robinson T, Linklater S, et al., 2022, Global Incidence, Prevalence and Mortality of Type 1 Diabetes in 2021 with Projection to 2040. Lancet Diabetes and Endocrinology, 10(10): 741–760.

Sherr J, Weinstock R, Bergenstal R, et al., 2024, Severe Hypoglycemia and Impaired Awareness Persist Despite Use of Diabetes Technology: Cross-sectional Survey. Diabetes Care, 47(6): 918–925.

Moon S, Jung I, Park C, 2021, Current Advances of Artificial Pancreas Systems: Comprehensive Review of Clinical Evidence. Diabetes and Metabolism Journal, 45(6): 813–839.

Page M, McKenzie J, Bossuyt P, et al., 2021, PRISMA 2020 Statement: Updated Guideline for Reporting Systematic Reviews. BMJ, 372: n71.

McAuley S, et al., 2022, Closed-loop Insulin Delivery Versus Sensor-augmented Pump Therapy in Older Adults with Type 1 Diabetes: Randomized Crossover Trial. Diabetes Care, 45(2): 381–390.

Boughton C, Hartnell S, Thabit H, et al., 2022, Hybrid Closed-loop Glucose Control Compared with Sensor Augmented Pump Therapy in Older Adults with Type 1 Diabetes: Multicentre Randomised Crossover Study. Lancet Healthy Longevity, 3(3): e135–e142.

Fang Z, Liu M, Tao J, et al., 2022, Efficacy and Safety of Closed-loop Insulin Delivery Versus Sensor-augmented Pump in Adults with Type 1 Diabetes: Systematic Review and Meta-analysis. Journal of Endocrinological Investigation, 45(3): 471–481.

Cyranka K, Matejko B, Juza A, et al., 2023, Quality of Life After One-year Use of Advanced Hybrid Closed-loop System in Adults with Type 1 Diabetes. Frontiers in Endocrinology, 14: 1210756.

Udsen F, Hangaard S, 2023, Effectiveness of Telemedicine Solutions in Type 1 Diabetes Management: Systematic Review and Meta-analysis. Journal of Diabetes Science and Technology, 17(3): 782–793.

Garg S, et al., 2023, Improved Glycemia with Hybrid Closed-loop Versus Continuous Subcutaneous Insulin Infusion Therapy in Type 1 Diabetes. Diabetes Technology and Therapeutics, 25(1): 1–12.